Skip to main content
Clinical Trials/NCT06276686
NCT06276686RecruitingPhase 1

A Single Arm Feasibility Study of Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer

University of Hull1 site in 1 country30 target enrollmentStarted: December 10, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
30
Locations
1
Primary Endpoint
Recruitment rate

Study Overview

Brief Summary

This is a single arm feasibility study of exercise for improving long- course neoadjuvant chemoradiotherapy (NACRT) efficacy in people diagnosed with locally advanced rectal cancer. The study aims to recruit up to 30 patients from the Queen's Centre for Oncology and Haematology of Castle Hill Hospital, Cottingham, diagnosed with locally advanced rectal cancer. Consenting patients will be provided with an 11-week course of structured aerobic exercises and resistance training in the periods before, during and after their chemoradiotherapy treatment. The patients will be followed up for 6 months post long course neoadjuvant chemoradiotherapy (NACRT), with a total of 3 assessment periods.

Detailed Description

This study will take place at Castle Hill Hospital, where the participants' usual care will be given. The study will also recruit at this site. Patients, who have been diagnosed with locally advanced rectal cancer (LARC) long-course chemoradiotherapy (NACRT) will be pre-screened for any obvious exclusions with those that are potentially eligible approached by their clinical oncologist to discuss participation in these studies. If the patient is agreeable, further contact will be made by a member of the research team for further discussion. The aim is to include about 30 participants in this study. The participant information sheet will be provided and any uncertainties about the study raised by the potential participant will be addressed. The potential participant will be given sufficient time, up to a week, to consider their participation in the study, as typically, there is on average a 31-day period between decision to treat and start of neoadjuvant oncological treatment. After all questions are answered and provided the participant is willing to take part in the study, they will be asked to sign the consent form to confirm participation.

Once a participant agrees to taking part, their medical history, and investigations (performed as part of routine clinical care) will be reviewed. Each participant's data from investigational phase for rectal cancer up to long-course NACRT completion and re-assessment will be collected. Data on age, gender, stage of rectal cancer, and any comorbidities will be collected from medical notes. Participants will then be invited for a baseline assessment at Castle Hill Hospital in a designated risk assessed rehabilitation gym.

In this baseline assessment, further personal details will be taken from the patient, including height and weight measurements to calculate Body Mass Index (BMI), other descriptive information such as ethnicity will also be taken. The Patient Reported Outcome Measures (PROMs) will be completed either independently by participant or with the help of a member of the research team if required by participant. Some of the questionnaires, such as the EORTC-QLQ-CR29 and FACT-C, contained in this study contain some questions that may be perceived to be intrusive. They however are validated questionnaires that have previously been used in numerous rectal cancer research studies. To mitigate embarrassment, participants will be forewarned about the contents of these questionnaires and potential to cause embarrassment. Participants will be reminded that their response will be anonymised. Questions relating to stoma and sex life are presented much later in the questionnaires where rapport may have already been established. Participants will be encouraged to consult with their oncologist if the questionnaires prompt any treatment related problems they may be experiencing.

Participants will also on this day, be provided an accelerometer to wear on 7 randomly selected days at different timeframes of the study. Finally on this day an average of three resting heart rates will be taken. The value of the average of the resting hear rates will be used in calculating a heart rate reserve (HRR) of 60%, 70% and 80%. Using the formula (HRmax-RHR) × exercise intensity (60-80%) + RHR, where HRmax is 220-Age as found to be more effective in recent research. This will form one of the main bases for exercise intensity, to ensure individualisation of the supervised vigorous intensity interval training sessions.

The supervised hospital-based exercise will be delivered over an 11-week period. This is because long-course neoadjuvant chemoradiotherapy lasts 5-weeks. This design allows for a 2-week pre-neoadjuvant oncological and a 4-week post-neoadjuvant oncological treatment. Exercise will involve an hour long, twice weekly vigorous intensity aerobic interval exercise and twice weekly supported at-home resistance training for all 11-weeks of the study. Vigorous intensity aerobic interval exercise will be performed at 70-80% of heart rate reserve (HRR).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years or older
  • •Have been diagnosed with locally advanced rectal cancer using MRI (Magnetic Resonance Imaging) and histological finding
  • •Have been offered long-course neoadjuvant chemoradiotherapy in the Queens Centre, Castle Hill Hospital
  • •Willing and able to comply with all study requirements
  • •Able and willing to voluntarily give informed consent to take part.

Exclusion Criteria

  • •Inability to understand basic written and spoken English, as research materials will all be written in English.
  • •Any movement deficiencies limiting ability to engage in exercise.
  • •Impaired cognition and/or capacity limiting ability to provide informed consent.
  • •Cardiovascular and/or cardiopulmonary conditions that will impede ability to safely perform exercise.
  • •Severe psychiatric disorders.
  • •With any other health condition which oncologists and research team agrees will impede ability to safely perform exercises.
  • •Presence of metastatic cancer.

Arms & Interventions

Single arm feasibility

Experimental

This study involves a single arm only. Therefore all consenting participants will receive the exercise intervention detailed in the protocol.

The exercise interventions include an 11-week aerobic and resistance training delivered 2-weeks before chemoradiotherapy commences , in the 5-weeks of chemoradiotherapy and 4 weeks following chemoradiotherapy.

2-days Aerobic exercise will be delivered on vigorous intensity on a cycle ergometer. This will be under the supervision of a trained physiotherapist. 2-days Resistance training will be home based with guidance of an exercise sheet.

Intervention: Supervised Vigorous intensity aerobic interval exercise (Other)

Outcomes

Primary Outcomes

Recruitment rate

Time Frame: This will be monitored in the total 6months of participants engagement if the study

The number of recruited participants/ total number of patients approached in percentage.

Attendance rate

Time Frame: This will be monitored in the total 6months of participants engagement if the study

The number of supervised exercise sessions attended/ total number of available supervised exercise sessions in percentage.

withdrawal rate

Time Frame: This will be monitored in the total 6months of participants engagement if the study

The number of participants who drop out of study/ total number of recruited participants in percentage.

Secondary Outcomes

  • Serum Carcinoembryonic antigen levels(up to 4 weeks before neoadjuvant chemoradiotherapy (NACRT), immediately following chemoradiotherapy and 6-months following NACRT)
  • FACT-C version 4 questionnaire for Quality of life(up to 4 weeks before NACRT, up to 1 week post NACRT and 6-months following NACRT)
  • EORTC-QLQ-CR29 questionnaire for Quality of life(up to 4 weeks before NACRT, up to 1 week post NACRT and 6-months following NACRT)
  • Physical activity levels(up to 4 weeks before NACRT, up to 1 week post NACRT and 6-months following NACRT)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials